12-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg and subdermal etonogestrel implant in adult women: A retrospective claims database analysis
Contraception Apr 26, 2018
Law A, et al. - The authors sought to investigate the 12-month discontinuation rates of levonorgestrel intrauterine system 13.5 mg (LNG-IUS 13.5) and subdermal etonogestrel (ENG) implant in the US. In this work, discontinuation was defined as presence of an insurance claim for pregnancy-related services, hysterectomy, female sterilization, a claim for another contraceptive method, or removal of the index contraceptive without re-insertion within 30 days. In the real-world US setting, they noted similar discontinuation rates among adult women using LNG-IUS 13.5 and ENG implant after 12 months.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries